Advocacy intelligence hub — real-time data for patient organizations
Ukoniq: FDA approved
treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn)
IMBRUVICA: FDA approved
Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn)
National Heart, Lung, and Blood Institute (NHLBI)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Ukoniq
TG Therapeutics, Inc.
IMBRUVICA
(ibrutinib)Orphan drugPharmacyclics, LLC
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine re...
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Véronique LEBLOND, Professor
French Study Group on Chronic Lymphoid Leukemia
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH
Thomas G. Martin, MD
University of California, San Francisco
Paul Martin
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Karen Syrjala
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA